

RESEARCH

Open Access



# Evolutionary genetics of pulmonary anatomical adaptations in deep-diving cetaceans

Boxiong Guo<sup>1</sup>, Yixuan Sun<sup>1</sup>, Yuehua Wang<sup>1</sup>, Ya Zhang<sup>1</sup>, Yu Zheng<sup>1</sup>, Shixia Xu<sup>1</sup>, Guang Yang<sup>1</sup> and Wenhua Ren<sup>1\*</sup>

## Abstract

**Background** Cetaceans, having experienced prolonged adaptation to aquatic environments, have undergone evolutionary changes in their respiratory systems. This process of evolution has resulted in the emergence of distinctive phenotypic traits, notably the abundance of elastic fibers and thickened alveolar walls in their lungs, which may facilitate alveolar collapse during diving. This structure helps selective exchange of oxygen and carbon dioxide, while minimizing nitrogen exchange, thereby reducing the risk of DCS. Nevertheless, the scientific inquiry into the mechanisms through which these unique phenotypic characteristics govern the diving behavior of marine mammals, including cetaceans, remains unresolved.

**Results** This study entails an evolutionary analysis of 42 genes associated with pulmonary fibrosis across 45 mammalian species. Twenty-one genes in cetaceans exhibited accelerated evolution, featuring specific amino acid substitutions in 14 of them. Primarily linked to the development of the respiratory system and lung morphological construction, these genes play a crucial role. Moreover, among marine mammals, we identified eight genes undergoing positive selection, and the evolutionary rates of three genes significantly correlated with diving depth. Specifically, the *SFTPC* gene exhibited convergent amino acid substitutions. Through in vitro cellular experiments, we illustrated that convergent amino acid site mutations in *SFTPC* contribute positively to pulmonary fibrosis in marine mammals, and the presence of this phenotype can induce deep alveolar collapse during diving, thereby reducing the risk of DCS during diving.

**Conclusions** The study unveils pivotal genetic signals in cetaceans and other marine mammals, arising through evolution. These genetic signals may influence lung characteristics in marine mammals and have been linked to a reduced risk of developing DCS. Moreover, the research serves as a valuable reference for delving deeper into human diving physiology.

**Keywords** Decompression sickness, Lung fibrosis, Amino acid substitution, Molecular evolutionary analysis, Cetaceans

\*Correspondence:

Wenhua Ren

08162@njnu.edu.cn

<sup>1</sup>Jiangsu Key Laboratory for Bioaffiliation and Biotechnology, College of Life Sciences, Nanjing Normal University, 210023 Nanjing, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Background

Human oceanic exploration has identified several dive-related illnesses, such as decompression sickness (DCS) [1, 2] and gas embolism [3]. DCS, being the most prevalent, is closely linked to various diving methods, including breath-hold diving [4–6] and scuba diving [7, 8]. In scuba diving, DCS mainly arises from the formation of gas bubbles in body tissues and blood, a result of rapid decompression. As divers inhale compressed air or gas mixtures at depth, elevated pressure leads to increased dissolution of nitrogen in their tissues [7, 8]. Should decompression transpire too rapidly during ascent or descent, nitrogen may effuse from the solution and form bubbles. These bubbles may induce a spectrum of symptoms, such as joint pain, nerve damage, and in extreme cases, paralysis or unconsciousness [1, 2]. Research indicates that DCS is a significant cause of fatality among scuba divers, second only to drowning [7]. Conducting multiple scuba dives in a short period significantly increases the risk of DCS and other related decompression illnesses [7, 8]. Although breath-hold divers do not inhale compressed gas and typically spend less time underwater, repeated deep dives over short intervals still increase their susceptibility to DCS. The risk of DCS in breath-hold diving rises with deeper dives and shorter surface intervals [4–6]. Breath-hold diving is predominantly observed in the animal kingdom. Post-activity neuroimaging studies of breath-hold divers have revealed DCS, evidenced by brain lesions [4]. Additionally, human divers who repeatedly dive to depths of 30–40 m or exceed 200 m in a single dive face increased DCS risk due to elevated nitrogen levels [5, 6]. Parallel research on wildlife, particularly loggerhead sea turtles (*Caretta caretta*), combines anatomical and physiological approaches. This research has identified clinical and pathological signs consistent with DCS in several captured specimens [9, 10].

DCS has been observed in various animals and humans participating in activities with variable pressure conditions [4–8, 10]. Marine mammals, particularly whales, engage in deep diving and may exhibit symptoms of DCS that are directly related to human activities, such as fishing and naval sonar interference [11–13]. However, these symptoms are not reported in their natural diving behavior, and instances of DCS are rare [13]. The reduced risk of DCS during diving may be linked to a specific lung phenotype, as supported by anatomical and physiological evidence [13–20]. Studies indicate that the thorax and lungs of many marine mammals are highly compliant, which may be related to the deep alveolar collapse and reinflation during dives [15, 21]. Research suggests that alveolar collapse, a primary mechanism in deep-diving marine mammals, limits nitrogen absorption and thereby mitigates the risk of DCS [13–15, 17, 22–26]. In these mammals, the alveolar walls are notably thickened [22,

27] and enriched with elastic fibers, exhibiting significant compliance and capable of reaching very low residual volumes (RV) [13, 15]. This trait likely aids in achieving negative buoyancy at depth and facilitating alveolar collapse, allowing for minimal dead space volumes and substantial tidal volumes (TV) for effective ventilation [22]. High thoracic compliance in marine mammals is also associated with this process [21]. In contrast, in typical animal lungs, an abundance of elastic fibers and thickened alveolar walls is often linked to pulmonary fibrotic diseases [28–30]. In humans, abundant elastic fibers and thickened alveolar walls typically lead to reduced lung compliance, adversely affecting breathing by making the lungs less expandable and impacting gas exchange efficiency [31]. However, marine mammals, such as cetaceans, exhibit exceptionally high lung compliance despite having thickened alveolar walls and an abundance of elastic fibers, a seemingly similar phenotype [21, 22]. This suggests cetacean lungs have unique regulatory mechanisms for more effective gas exchange during dives, preventing diving-related diseases, especially DCS.

Studies on cetaceans reveal that their lungs collapse during dives and re-expand upon ascent [14, 15, 17, 22]. Marine mammals possess pulmonary surfactants with enhanced capabilities to reduce alveolar surface tension compared to other animals [22, 32, 33]. This enhanced function facilitates the re-expansion of collapsed alveoli during the ascent phase of diving, effectively preventing potential harm from lung squeeze. This indicates that marine mammal surfactants are optimized for their aquatic lifestyle, ensuring physiological safety and health during frequent deep dives and ascents [22, 32, 33]. The surfactant system, in conjunction with structural adaptations of the respiratory system, plays a pivotal role in protecting against both lung squeeze and pulmonary barotrauma, thereby maintaining the integrity of the respiratory function in these animals [22, 32, 33]. Recent advancements in marine mammal respiratory physiology have led to the formulation of the “*Selective Gas Exchange hypothesis*” [13, 14]. This hypothesis explicates the mechanisms by which cetaceans and other marine mammals minimize nitrogen (N<sub>2</sub>) absorption while diving. Featuring a unique lung architecture with collapsible alveolar regions, and through the alignment of pulmonary blood flow with these regions, cetaceans can selectively exchange oxygen (O<sub>2</sub>) and carbon dioxide (CO<sub>2</sub>), while minimizing N<sub>2</sub> exchange [13, 14]. Consequently, this reduces the risk of DCS in whales during dives. Similar observations in other marine mammals, such as *Lepidonchotes weddelli*, show alveolar collapse correlating with diving depth [23, 26]. This indicates that for deep-diving marine mammals, profound alveoli collapse may benefit oxygen and carbon dioxide exchange during dives, inhibiting nitrogen absorption and thereby reducing DCS

risk [17, 19, 34]. Molecular studies have identified two genes, *MAP3K19* and *SEC14L3*, lost exclusively in Cetacea and primarily expressed in the lungs [24]. *MAP3K19*, found in bronchial epithelial cells, type II pneumocytes, and lung macrophages [35], is implicated in pulmonary fibrosis [35] and chronic obstructive pulmonary disease (COPD) [36]. Inhibiting *MAP3K19* in mice models has shown a reduction in fibrosis and collagen deposition, thus preventing pulmonary fibrosis [35]. Additionally, this inhibition significantly diminishes lung inflammation and airway destruction, facilitating elastic fiber production, which is beneficial for alveolar collapse during diving [36]. *SEC14L3*, expressed in ciliated airway cells and type II pneumocytes, is involved in producing pulmonary surfactant, which prevents alveolar collapse [37–39]. The loss of *SEC14L3* in cetaceans may affect the surfactant's composition and anti-adhesive properties [24]. Based on the anatomical and genomic evidence presented, we propose that the lungs of marine mammals, characterized by a high density of elastic fibers and a notable degree of flaccidity, are adapted to achieve low RV. This adaptation facilitates negative buoyancy and promotes alveolar collapse at depth. Additionally, pulmonary surfactant plays a critical role in ascending from dives. It aids in the expansion of alveoli and mitigates the risk of pressure-induced lung injuries and reduces the incidence of DCS during dives [22].

The advancement of sequencing technologies and the increasing abundance of mammalian genomic data afford an unparalleled opportunity to explore the molecular mechanisms underlying the pulmonary morphological features of cetaceans, as well as their adaptations to mitigate the risk of DCS during prolonged dives. In this study, we utilized a functional genomics approach to assess the evolution of 42 genes across 45 mammalian species, encompassing both cetaceans with high-quality genomes and their terrestrial counterparts. By integrating bioinformatic analysis with in vitro functional experiments, this study offers insights into the divergences in lung morphology among marine mammals and the molecular mechanisms that mitigate the risk of DCS during dives. These findings enhance our comprehension of the anatomy and physiology related to DCS and shed light on the evolutionary adaptations of marine mammals.

## Methods and materials

### Species coverage and sequence acquisition

In our study, we investigated 45 mammalian species with high-quality sequencing and assembly, representing a wide range of classifications (include species with a pulmonary fibrosis phenotype and their close relatives). The selected species belong to different orders including: Cetartiodactyla (*Tursiops truncatus*, *Orcinus orca*, *Delphinapterus leucas*, *Lipotes vexillifer*, *Physeter catodon*,

*Balaenoptera acutorostrata*, *Balaenoptera musculus*, *Globicephala melas*, *Lagenorhynchus obliquidens*, *Monodon monoceros*, *Neophocaena asiaorientalis*, *Phocoena sinus*, *Bos taurus*, *Ovis aries*, *Sus scrofa*, *Bos mutus* and *Bos grunniens*), Perissodactyla (*Equus caballus* and *Equus asinus*), Carnivora (*Odobenus rosmarus*, *Phoca vitulina*, *Leptonychotes weddellii*, *Neomonachus schauinslandi*, *Callorhinus ursinus*, *Eumetopias jubatus*, *Zalophus californianus*, *Halichoerus grypus*, *Mirounga leonine*, *Canis familiaris*, *Ailuropoda melanoleuca* and *Ursus maritimus*), Chiroptera (*Rhinolophus ferrumequinum*), Eulipotyphla (*Erinaceus europaeus*), Proboscidea (*Loxodonta africana*), Sirenia (*Trichechus manatus*), Pilosa (*Cholepus didactylus*), Dasyuromorphia (*Sarcophilus harrisii*), Ornithorhynchidae (*Ornithorhynchus anatinus*), Primates (*Homo sapiens*, *Rhinopithecus roxellana* and *Rhinopithecus bieti*), Rodentia (*Mus musculus* and *Rattus norvegicus*), and Lagomorpha (*Oryctolagus cuniculus* and *Ochotona curzoniae*) (Table S2).

The gene set associated with pulmonary fibrosis disease was collected from several previously published articles [40–43], as well as a database using the keyword ‘pulmonary fibrosis’ (<https://www.informatics.jax.org/>) (Table S1). The protein-coding sequences (CDS) were downloaded from the NCBI database (<https://www.ncbi.nlm.nih.gov/>) (Table S3). In addition, custom perl scripts were used to perform BLASTn searches to further verify partially or unannotated CDS. The longest transcript was retained for each gene in this analysis. To obtain higher quality sequences, we performed multiple sequence alignments for each orthologous gene using MACSE v2 [44] combined with PRANK v.170427 [45]. The aligned sequences were then trimmed using Gblocks v0.91 [46] with default settings.

### Molecular evolutionary analysis

Comparisons of nonsynonymous (dN)/synonymous (dS) substitution ratios have become a useful means for quantifying the impact of natural selection on molecular evolution [47, 48]. We employed the CODEML model implemented in the PAML 4.7 [49] software to perform codon-based maximum likelihood estimation of  $\omega$  values. Values of  $\omega < 1$ ,  $= 1$ , and  $> 1$  correspond to purifying selection, neutral evolution, and positive selection, respectively [50]. Considering the influences of base transition/transversion rates and codon usage in molecular evolution [51], we employed likelihood ratio tests (LRTs) to compare the hypotheses within each pair of nested models. To account for multiple testing, we utilized the Benjamini-Hochberg method [52] and set a false discovery rate (FDR) cutoff of 0.05.

To identify REGs in cetaceans, the two-ratio model in PAML was employed [49–53]. The null hypothesis (one-ratio model) assumed that genes in all-mammals

evolved with the same  $\omega$ , while the alternative hypothesis set two different  $\omega$  values for the foreground (cetacean) and background (other mammal) species. Genes with  $\omega$  (cetaceans)  $>$   $\omega$  (other mammals) were considered REGs in cetaceans [50].

To test whether positively selected sites were limited to a specific lineage, we used branch-site model and free-ratio model in the CODEML program to analyze the all-mammals dataset. The branch-site model can detect positive selection at specific sites along a specific branch, in both the null hypothesis (Ma0) and alternative hypothesis (Ma), distinctions in  $\omega$  values are permitted among foreground and background branches and within sites in each gene. Under the Ma0 model, all species and sites are assumed to have  $\omega$  values that do not exceed 1, indicating the absence of positive selection signals. In contrast, the Ma model permits certain sites in the foreground branch (cetaceans) to have  $\omega$  values greater than 1, indicating the presence of positively selected sites [54, 55]. Whereas the free-ratio model allows an independent  $\omega$  value for each branch [49], we compared the free-ratio model that assumes an independent  $\omega$  ratio for each branch with the null one-ratio model with the same  $\omega$  for all branches. When the value of dN or dS in each  $\omega$  value is less than 0.0002, we considered it as an outlier “n/a” [56]. The relative goodness-of-fit of the nested models was determined using LRTs. All nested models were statistically different from the null model ( $P < 0.05$ ) [57].

#### Identification of specific and convergent amino acids

We used the Fasparser 2.0 [58] to detect specific amino acids in cetaceans and convergent amino acids in marine mammals, respectively. Human canonical sequences in UniProt (<https://www.uniprot.org/>) [59] were taken as references for the locations of amino acids.

#### Mapping of positively selected sites and cetacean-specific sites onto protein structures

To investigate the impact of positively selected sites and cetacean-specific sites on protein function. We used Swiss-Model (<https://swissmodel.expasy.org/>) [60] to predict the 3D structure, then used the Pfam (<http://pfam.xfam.org/>) [61] website to search for domains of each protein. Finally, the EzMol (<http://www.sbg.bio.ic.ac.uk/~ezmol/>) [62] was used to annotate the positively selective sites and functional domains in the obtained 3D structure.

#### Association analysis between gene evolution and diving depth

In order to investigate the potential relationship between the gene evolutionary rate ( $\omega$ ) and maximum diving depth, we utilized root-to-tip  $\omega$ , which refers to the average  $\omega$  value accumulated from the last common ancestor

to the extant species and serves as a selection indicator encompassing the evolutionary history of the gene within a given species [63, 64]. The evolutionary rate of each gene was calculated using codeml in PAML [49] with a free-ratio model. The diving depth data of marine mammals were collected from previously published sources (Table S7). PGLS regression [65] was used to analyse the relationship between log (root-to-tip  $\omega$ ) and log (maximum-diving depth m). The lambda ( $\lambda$ ) value estimated by the maximum likelihood method was used as a quantitative measure of phylogenetic signals [66]. All statistical analyses were performed using R in the package Caper [67].

#### Gene functions and signaling pathway annotation and enrichment

The genes were subjected to GO functional [68] enrichment analyses using the Metascape (<http://metascape.org>) [69]. In Metascape, we set *Homo sapiens* as the “Input as species” and “Analysis as species” and used a cutoff of  $p$ -value  $<$  0.05.

#### Cell culture, lentiviral production and infection

Human NSCLC cell line A549 cells was purchased from ATCC and cultured according to the protocols of the ATCC. All culture media were purchased from WISENT, cell culture dishes were purchased from Jet Biofil. The sequence of Whale-SFTPC was generated in Beijing Tsingke Biotech Co. Ltd. Lentiviral vectors (Lentivirus-mCherry-Puro-CMV-N3xFlag-BI-SFTPC/mutSFTPC, Lentivirus-mCherry-Puro-CMV-N3xFlag-Mouse-SFTPC/mutSFTPC) were produced by Corues Biotechnology Company (Nanjing, China), and lentiviral infection protocol followed the company’s instructions. The sequence is shown in the Table S11.

#### DNA extraction and PCR amplification

Fresh mouse lung tissue samples were utilized, and RNA was extracted from these samples following the standard phenol-chloroform extraction protocol. Mice were euthanized by cervical dislocation and acquired from GemPharmatech Co., Ltd. (Nanjing, China). The cDNA of mouse SFTPC was amplified using PCR. PCR profiles were 95 °C/5 min, 95 °C–30 s, 70 °C–30 s, 72 °C–40 s, and 72 °C/5 min cycles, repeated 35 times. PCR products were directly sequenced using an ABI 3730 DNA sequencer (Sangon Biotech, Shanghai Co., Ltd.). The construction of mouse and cetacean SFTPC gene mutants with individual amino acid mutations (I123V, V123I) followed the instructions of the Beyotime (Shanghai, China) Quick Mutation kit. All primers used for amplification are listed in Table S10.



### Antibodies

Antibodies used were as follows: antibodies against Cleaved-Caspase 3 (cat# 9664), was purchased from Cell Signaling Technology, Inc., Danvers, MA, USA; antibodies against MMP7 (cat# A20701), ACTA2 (cat# A17910) were purchased from ABclonal (Wuhan, China); antibodies against SFTPC (cat#10774-1-AP) and beta-Tubulin (cat# 10094-1-AP) were purchased from Proteintech Group, Rosemont, IL, USA.

### Western blotting

Collect the cells and lyse them in cell lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NonidetP-40, 0.5% sodium deoxycholate, and 1% protease inhibitor cocktails, MCE), centrifuge the cell lysate at 4 °C, 14,000 rpm for 15 min. In Western blot studies, protein concentrations of samples were determined using the Bradford protein method, and 20 µg of proteins for each sample were separated by SDS-PAGE followed by transfer to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked for 1 h at room temperature with 5% nonfat milk in the TBST buffer and incubated with a specific primary antibody diluted in TBST buffer overnight at 4 °C. After extensive washes by TBST buffer, the membranes were incubated with a corresponding secondary antibody for 1 h at room temperature, and the immunoreactive bands were visualized by using an ECL kit (Vazyme Biotech Co. Ltd., Nanjing, China).

### Cell viability assay

Cell proliferation was assessed through CCK8 assays. Cells were briefly seeded at  $3 \times 10^3$  cells/well in triplicate in a 96-well plate and cultured overnight. At 24 h and 48 h, 10 µL of CCK8 solution (Vazyme Biotech Co. Ltd., Nanjing, China) was added to each well, followed by incubation at 450 nm for an additional 2 h using a microplate reader to measure absorbance. Cell viability for each treatment was determined as a percentage of its OD<sub>450 nm</sub> compared to the vehicle control, calculated using GraphPad Prism 8.0 software.

### Statistical analysis

Experiments were carried out at least 3 times unless otherwise stated. The software GraphPad Prism 8.0 was used for statistical analysis and the data are shown as mean ± S.D. Student's t-test and one way ANOVA were employed to assess the statistical significance of differences between data sets. A *p*-value of lower than 0.05 was considered to be significant. *p* < 0.05 (\*), *p* < 0.01 (\*\*), and *p* < 0.001 (\*\*\*)

## Results


### Rapidly evolving genes and positively selected genes in cetaceans

Positive selection and rapid evolution of specific genes result from the accumulation of genetic variation in response to environmental changes, a component of Biological Adaptation to Natural Selection [70]. In this study, we employed the Consensus Tree from TimeTree (Fig. S1) and the CODEML model in PAML to detect rapidly evolving genes (REGs) and positively selected genes (PSGs) across 45 mammalian species, designating cetaceans as the foreground species and other mammals as the background. Employing branch model analyses with CODEML, we identified 21 REGs in cetaceans, adjusting for multiple testing using the FDR method (adjusted *p*-value < 0.05) (Table S4). The evolutionary rates of these genes were notably higher in cetaceans than in other mammalian species (Fig. 1A), implying unique selective pressures on cetaceans. Enrichment analysis further disclosed that REGs in cetaceans were linked to respiratory gaseous exchange by the respiratory system, diseases associated with surfactant metabolism, blood vessel development, and blood vessel morphogenesis (Fig. 1B).

The Branch model (One-ratio vs. Free-ratio) and Branch-site models were utilized to identify positive selection in eight cetacean genes [71] (Table S5, Table S6). Four of these genes (*SFTPB*, *SFTPC*, *MMP7*, *HLA-DRB1*) exhibited positive selection in the background branch species as well (Fig. 1C). To establish the relationship between the proposed positively selected amino-acid sites and protein function, we conducted a search on the UniProt database to map these sites onto their respective 3D structures. The results revealed that certain positively selected amino-acid sites were located within crucial functional domains of proteins (Fig. S2). Specifically, site 40 and 69 of *MMP7* exhibit positive selection in the Putative peptidoglycan binding domain, and sites 104, 115, 121, 131 are situated in the Matrixin domain. Previous reports indicate that *MMP7* overexpression induces apoptosis of alveolar epithelial cells and migration of interstitial cells, leading to the destruction of the alveolar wall and the development of pulmonary fibrosis [43, 72] (Fig. S2).

### Specific amino acid substitutions in cetaceans

Fixed amino acid replacements within a specific group of mammals may contribute to explaining a particular phenotype [56]. We detected 28 cetacean-specific amino acid substitutions in 14 proteins (Fig. 2). Enrichment analysis unveiled associations of the genes encoding these proteins with inflammatory response, lung development, and respiratory system development (Fig. S3). Mapping the cetacean-specific sites to their respective 3D structures was done to assess their functional relevance. The results



**Fig. 1** REGs and PSGs that were identified using PAML. **(A)** Twenty-one REGs in cetaceans with  $\omega_{\text{cetaceans}} > \omega_{\text{other mammals}}$  (adjusted  $p$ -value  $< 0.05$ ). **(B)** GO enrichment terms for Twenty-one REGs in cetaceans. The 20 related terms in biological process are shown. **(C)** Evidence of positive selection across the phylogeny of mammals identified by the free-ratio and branch-site models. In the phylogenetic tree, blue represents marine mammals, and orange represents terrestrial mammals. Triangles and circles represent the free-ratio and branch-site models, respectively. The silhouette pictures are from the Internet

revealed that certain sites were located within crucial functional domains of proteins (Fig. S4). As an example, the cetacean SERPINE1 protein exhibited a specific amino acid site (53) within the Serpin (serine protease inhibitor) domain. Previous reports indicate that mutations or functional defects in the Serpin domain may result in the loss of its ability to inhibit protease activity, contributing to its functional abnormality in pulmonary fibrosis [73, 74] (Fig. S4).

**Association between gene evolution and maximum diving depth**

Evaluating the statistical association between genes and normal phenotypic variation is a well-regarded strategy for investigating the phenotypic implications of an ongoing selection signature [75]. Phylogenetic generalized least squares (PGLS) regressions were conducted to explicitly explore the connection between the evolutionary rate of genes and maximum diving depth. Regression analyses demonstrated a significant positive association between  $\log_{10}$  (root-to-tip  $\omega$ ) and  $\log_{10}$


(max-dive-depth m) in three genes, namely *BDKRB1* ( $R^2=0.160, p=0.0434$ ), *PINK1* ( $R^2=0.208, p=0.0272$ ), and *RTEL1* ( $R^2=0.072, p=0.0382$ ) (Fig. 4, Table S7, Table S8).

**Functional convergence of the SFTPC among marine mammals**

Initial observations revealed convergent/parallel amino acid substitutions in the SFTPC protein (SP-C) among 23 marine mammals (excluding *Trichechus manatus*). At position 123 of the SP-C, marine mammals exhibit Valine, while terrestrial mammals display Isoleucine (Fig. 3A). To ascertain the relationship between this convergent site and protein function, we mapped the site onto the three-dimensional structure of the SP-C. The results indicated that the site is situated in the BRICHOS domain of the SP-C (Fig. 3B).

**Correlation between SFTPC gene mutations and protein expression of pulmonary fibrosis markers**

We investigated whether convergent evolutionary site variations in the *SFTPC* gene in marine mammals



**Fig. 2** Specific amino acid substitutions in cetaceans. Fourteen proteins were identified to have undergone specific amino acid substitutions, indicated by red text for cetaceans and black text for other mammals. Different colors are used to represent different amino acids at the same position in the protein

enhance pulmonary fibrosis, leading to alveolar collapse during diving and potentially reducing the risk of DCS. Various *SFTPC* variants were overexpressed, and western blotting techniques were utilized to assess whether variations in *SFTPC* gene loci induce alterations in the expression levels of fibrotic marker proteins, including MMP7 (Matrix Metalloproteinase 7) and  $\alpha$ -SMA (Alpha-Smooth Muscle Actin). The results show that in whales, the expression levels of MMP7 and  $\alpha$ -SMA proteins in wild-type individuals are higher than those in the control and mouse wild-type. Additionally, in whale mutants, there is a decrease in the expression of both MMP7 and  $\alpha$ -SMA proteins compared to their wild-type counterparts. In mouse mutants, there is an increase in MMP7 protein expression relative to their wild-type, but no significant change in  $\alpha$ -SMA protein expression (Fig. 5A).

**Correlation between *SFTPC* gene mutations and cell proliferation and apoptosis abilities**

The regulatory mechanisms connecting pulmonary fibrosis and endoplasmic reticulum (ER) stress are intricately linked [76]. Subsequently, we conducted a thorough investigation to determine whether lung fibrosis resulting from *SFTPC* gene mutations influences cellular


proliferation and apoptosis during the ER stress phase. Initially, we evaluated cell proliferation levels after over-expressing various *SFTPC* variants. Our results indicate that in cell proliferation assays, the five experimental groups exhibited higher cell proliferation capabilities at 24 and 48 h in both wild-type and mutant mice compared to wild-type and mutant whales. No significant changes were observed in proliferation capabilities between wild-type and mutant whales compared to the control and between wild-type and mutant mice (Fig. 5B, Table S9). We then analyzed alterations in the expression levels of the apoptotic effector, Cleaved-caspase 3, using protein assays. We observed that, compared to the control, the expression level of Cleaved-caspase 3 increased in wild-type whales, and it was higher in wild-type mice compared to wild-type whales (Fig. 5C).

**Discussion**

Cetaceans are mammals that have completely transitioned from a terrestrial to an aquatic lifestyle, and their respiratory systems have undergone adaptive changes to cope with the process of breathing in the ocean. The lungs, among these adaptations, serve as a crucial interface between the body and the environment








**Fig. 4** Regression analyses between root-to-tip  $\omega$  and maximum diving depth. Scatterplots of significant relationships between  $\log_{10}(\text{max-dive-depth m})$  and  $\log_{10}(\text{root-to-tip } \omega)$

We propose that *RXFPI* pathways or similar mechanisms may underlie the superior pulmonary function observed in marine mammals. These animals exhibit remarkable lung compliance, possibly due to *RXFPI*-mediated modulation of tissue remodeling and fibrosis [81, 82]. This regulatory process resembles the *MAP3K19*-induced inhibition of lung fibrosis, indicating potential regulatory overlaps in marine mammal lung fibrosis [24]. Such mechanisms could enable these lungs to remain highly compliant despite the presence of significant fibrous tissue. The *PLAU* gene encodes an enzymatic protein known as plasminogen activator [84]. Research has demonstrated the pivotal role of *PLAU* in hypoxia adaptation

for cetaceans [85]. This study primarily employed a genome-wide large-scale screen, determining the association of the *PLAU* gene with hypoxia adaptation in porpoises and its likely prominent role in hypoxic responses [85, 86]. *PLAU* also promoted Esophageal squamous cell carcinoma proliferation and colony formation through MAPK pathway, and promoted migration through up-regulation of Slug and MMP9, leading to an increase in fibrosis [84]. Similarly, numerous genes play roles in lung development, such as *ABCA3*. The *AP3B1* gene encodes the  $\beta 3A$  subunit of the adaptor protein complex 3 (AP-3), and mutations in the *AP3B1* gene result in Hermansky-Pudlak syndrome (HPS) subtypes HPS-2 and HPS-10



**Fig. 5** The convergent site of *SFTPC* gene enhances pulmonary fibrosis in marine mammals. *SFTPC* overexpression in A549 cell lines, Western blot analyses of pulmonary fibrosis markers (A) and apoptotic marker (C). (B) CCK8 assays detected the effects of after overexpressing *SFTPC* on the proliferation of A549 cell lines. EV is Lev-mCherry-Puro-CMV-N3xFlag-control, M is Lev-mCherry-Puro-CMV-N3xFlag-Mouse-SFTPC, W is Lev-mCherry-Puro-CMV-N3xFlag-BI-SFTPC, M(mut) is Lentivirus-mCherry-Puro-CMV-N3xFlag-Mouse-mutSFTPC, W(mut) is Lentivirus-mCherry-Puro-CMV-N3xFlag-BI-mutSFTPC. Data represent the mean  $\pm$  S.D. \* $p < 0.05$ , \*\* $p < 0.01$ . The cell lysates were subjected to Western blot analyses using indicated antibodies with Tubulin as a loading control. The blots/gels displayed in the figure represent cropped versions, delineated by black dividing lines. Full-length blots/gels are presented in Fig S5

[87]. Pulmonary fibrosis develops in HPS-1, HPS-2, and HPS-4 [87, 88]. The findings indicate that the adaptive evolution of genes associated with pulmonary fibrosis may play a role in the development of diverse elastic fiber and thickening of alveolar walls phenotypes in cetacean lungs [22]. These findings enhance our comprehension of the variations in lung morphology and anatomy among marine mammals. They offer insights into the molecular mechanisms underlying breath-holding capabilities and the reduction of DCS risk in these animals.

#### The high abundance of elastic fibers in the lungs is a common strategy among marine mammals to reduce the risk of DCS in hypoxic environments

The mechanisms marine mammals, including cetaceans, use to mitigate DCS risk during prolonged dives have been extensively investigated. Macroscopic evidence shows that their lungs, enriched with loosely distributed elastic fibers, enable a deep collapse during dives, reducing DCS risk. The primary support for this comes from anatomical studies [22]. However, there is a significant lack of molecular evidence from an evolutionary standpoint.

By comparing two models (branch model and branch-site model) using PAML, a prevalence of positive selection was found in lung fibrosis-related genes among marine mammals, with the majority of positively selected sites situated in crucial functional protein domains. In humans and other mammals, elastic fibers in the lungs constitute a minimal proportion [89], ensuring optimal elasticity and morphological stability for efficient gas exchange and respiratory function [89, 90]. While a thickened alveolar wall and a large number of elastic fibers in the lungs may induce lung fibrosis in typical mammals, resulting in respiratory challenges, marine mammals do not experience such issues. This phenomenon may be attributed to cetaceans' possession of a dual capillary network in the lungs [22, 91], enhancing gas exchange between alveoli and capillary blood, averting respiratory distress despite fibrosis. Concerning the maintenance of high pulmonary compliance in marine mammals with this distinct phenotype [21], we propose the existence of supplementary regulatory mechanisms within the lungs that govern this process. Additionally, our research indicates that the evolution of the *RXFP1* gene may be pivotal in controlling pulmonary fibrosis, thus facilitating the

preservation of high pulmonary compliance and significantly improving respiratory efficiency while diving [81, 82]. The elevated fibrosis in cetacean lungs suggests that lung fibrosis-related genes have undergone adaptive evolution in marine mammals to facilitate their diving and respiratory processes. Eight lung fibrosis-related genes were identified: *BDKRB1*, *CHRM3*, *HLA-DRB1*, *MMP7*, *PLAU*, *SETD2*, *SFTPB*, and *SFTPC*. *BDKRB1* encodes the bradykinin B1 receptor, binding to the peptide hormone bradykinin and engaging in various inflammatory response processes [92]. Studies have demonstrated that the deletion of *BDKRB1* in mice inhibits fibrosis [92], suggesting the receptor's role in promoting fibrosis and its potential significance in mammalian lung fibrosis [92]. *SFTPB* and *SFTPC* genes encode vital components of pulmonary surfactant, crucial for regulating alveolar surface tension and maintaining lung tissue architecture [93, 94]. Mutations in the *CHRM3*, *HLA-DRB1*, *PLAU*, and *SETD2* genes are closely linked to the pathogenesis of pulmonary fibrosis [40, 86, 95, 96]. The *MMP7* gene, serving as a biomarker for pulmonary fibrosis, has been demonstrated to contribute to the development of lung fibrosis through its elevated expression [43, 72].

Simultaneously, correlation analysis reveals a positive relationship between the evolutionary rates of the *BDKRB1*, *PINK1*, and *RTEL1* genes and maximum diving depth. The functions of these genes are linked to the formation of pulmonary fibrosis, implying their significant role in the diving process of cetaceans. For example, research has demonstrated that mutations in the *RTEL1* gene contribute to an animal's adaptation to hypoxic conditions [97]. In mice, the reduction of *PINK1* expression in lung epithelial cells resulted in mitochondrial depolarization and the expression of profibrotic factors [98]. The collective findings indicate that the adaptive evolution of genes linked to pulmonary fibrosis in marine mammals offers insights into the variations in their lung morphology and the associated risk of developing DCS due to lung collapse [22, 98].

#### **The evolution of *SFTPC* may have contributed to pulmonary fibrosis in marine mammals**

Pulmonary surfactant, composed of lipids and proteins, is crucial for alveolar stability, surface tension reduction, and gas exchange in the lungs [32]. *SFTPC*, encoding a hydrophobin SP-C in type II alveolar epithelial cells, is integral to these functions [99]. The BRICHOS domain (residues 94–197) in SP-C prevents protein aggregation, ensuring proper folding and stabilization [100, 101]. The BRICHOS domain assists in the proper folding and stabilization of SP-C, preventing the formation of toxic aggregates in the alveoli and enabling its normal biological function [76]. Previous research has found that mutations in the *SFTPC* gene are associated

with several familial and sporadic interstitial lung diseases, including pulmonary fibrosis [102–104]. These mutations can lead to abnormalities in the structure and function of the SP-C, affecting the composition and function of pulmonary surfactant, ultimately resulting in lung tissue damage and fibrosis [76]. Several studies have linked mutations in *SFTPC* within the BRICHOS domain of the proprotein (proSP-C) to interstitial lung diseases [101, 105]. For example, DNA sequence analyses of the *SFTPC* in children with nonspecific interstitial pneumonia and adults with usual interstitial pneumonia have identified a common heterozygous mutation in exon 5 [106]. This mutation causes a Leu188 to Gln188 change in the carboxy-terminal region of SP-C, potentially impacting peptide processing [106]. These observations suggest that individuals with this specific mutation in the *SFTPC* may have an increased risk of various types of interstitial lung diseases [106]. Using SP-C $\Delta$ exon4 as a model molecule, a study provides evidence supporting the concept that misfolded BRICHOS mutant isoforms could induce cell injury by disrupting two separate but mechanistically linked subcellular systems, the unfolded protein response (UPR) and the ubiquitin-proteasome system (UPS) [101]. In summary, mutations occurring in the BRICHOS domain of SP-C have been associated with interstitial lung diseases, including pulmonary fibrosis. These mutations can lead to abnormal protein structure and function, affecting the composition and function of pulmonary surfactant, and contributing to lung tissue damage and fibrosis [76, 105, 107–109].

Moreover, our investigation demonstrates that a mutation at position 123 of the *SFTPC* gene, situated within the BRICHOS domain in whales, induces an upregulation of the lung fibrosis marker proteins MMP7 and  $\alpha$ -SMA. Comparative analysis reveals heightened MMP7 protein expression in whales compared to wild-type mice. Rescue experiments further indicate increased MMP7 expression in mutant mice compared to their wild-type counterparts, whereas in whale mutants, MMP7 expression is reduced compared to wild-type mice. Similarly,  $\alpha$ -SMA protein expression is elevated in whales relative to wild-type mice, with no increase observed in mutant mice compared to wild-type. Consistent with previous research, it is recognized that heightened MMP7 and  $\alpha$ -SMA expression contributes to the advancement of pulmonary fibrosis [43, 72, 110]. Building upon prior research, we have identified that marine mammals' pulmonary surfactant significantly enhances the reduction of alveolar surface tension [33]. This enhancement is vital for alveolar re-expansion during the ascent phase of diving, effectively mitigating the risk of lung squeeze injuries due to alveolar collapse [22, 32, 33]. Additionally, our research elucidates the molecular role of SP-C in pulmonary fibrosis development. This insight not only

corroborates the evolutionary adaptation of the lung phenotype in marine mammals but also suggests that the copious, loosely organized elastic fibers in their lungs play a crucial role not only in facilitating alveolar collapse during diving but also in supporting lung expansion upon ascent [22]. In both wild-type and mutant mice, the expression levels of  $\alpha$ -SMA protein vary. We believe that amino acid substitutions may have varying effects on protein stability and function in different organisms, and can also affect interactions with other proteins, thereby leading to differences in protein expression levels [111]. The abnormal excessive apoptosis of alveolar epithelial cells is one of the important characteristics of the development of COPD [112, 113]. Therefore, we further investigate the levels of cell proliferation and apoptosis. The cell proliferation assay indicated that at 24 and 48-hour intervals, the proliferation of cetacean wild-type and mutant A549 cells showed no significant change compared to the blank control and murine wild-type and mutant variants. However, apoptosis assays revealed an increase in Cleaved-caspase 3 expression in both wild-type and mutant groups of cetaceans and mice compared to the control, indicating apoptosis occurred in all experimental groups. Notably, more apoptosis was observed in the murine wild-type cells compared to the cetacean mutant variants. Our findings further corroborate previous discoveries that pulmonary fibrosis-induced damage to alveolar epithelial cells leads to an increase in apoptosis levels, while not affecting proliferation levels [114, 115]. Compared to the wild-type cells of mice, there is a reduced level of apoptosis in the wild-type cells of whales. We hypothesize that this could be attributed to adaptive mechanisms evolved by cetaceans due to their prolonged underwater lifestyle. These mechanisms, occurring alongside pulmonary fibrosis in whales, reduce the damage to alveolar epithelial cells, thereby facilitating their respiratory function during diving activities. These results suggest that marine mammals, including whales, have adapted to their long-term aquatic environment by evolving a distinctive phenotype in their lungs. This phenotype is characterized by a marked thickening of the alveolar walls and an abundance of loosely distributed elastic fibers [22, 27].

## Conclusions

To elucidate the molecular mechanisms employed by cetaceans to mitigate the risk of DCS during deep dives, we conducted a comprehensive investigation into 42 lung fibrosis-related genes across representative mammalian lineages. Our findings unveil accelerated evolution, specific amino acid substitutions, and positive selection in multiple lung fibrosis-related genes within cetaceans. This suggests an evolution in their respiratory systems, facilitating diving and minimizing the risk of DCS. Convergent positive selection and amino acid substitutions

were also observed in marine mammals. Combined with *in vitro* experimental validation of the *SFTPC* gene, these results indicate the contribution of lung fibrosis genes to the capacity of marine mammals to reduce the risk of DCS during diving. Moreover, we observed a notable correlation between the rate of gene evolution and diving depth, which reinforces the *selective gas exchange* hypothesis in marine mammals at a molecular scale [13, 14]. This hypothesis elucidates the mechanism by which cetaceans minimize the absorption of N<sub>2</sub> during dives. They achieve this through a specialized lung structure featuring collapsed alveolar regions, coupled with the regulation of blood flow to these areas, thereby enabling selective O<sub>2</sub> and CO<sub>2</sub> exchange with minimal nitrogen exchange [13, 14]. In conclusion, the evolutionary patterns of lung fibrosis-related genes provide novel insights into lung morphology in marine mammals. This research not only enhances our understanding of the molecular evolutionary adaptations of cetaceans to aquatic life but also holds promise for developing strategies to prevent and treat DCS in humans.

## Abbreviations

REGs	Rapidly evolving genes
PSGs	Positively selected genes
COPD	Chronic obstructive pulmonary disease
DCS	Decompression sickness
SFTPC	Surfactant Protein C
PAML	Phylogenetic analysis by maximum likelihood
BLAST	Basic local alignment search tool
PGLS	Phylogenetic generalized least squares
LRT	Likelihood ratio test
FDR	False discovery rate
GO	Gene Ontology

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12864-024-10263-9>.

Supplementary Material 1

Supplementary Material 2

## Acknowledgements

We thank Dr. Tianzhen Wu, Dr. Xu Zhou and all other members of Jiangsu Key Laboratory for Biodiversity and Biotechnology for suggestions and support during the project.

## Author contributions

WR, GY and SX conceived the study and assisted with manuscript revision. BG and YZ collected the data, BG performed the molecular evolution analysis and wrote the paper. YS, YZ and YW conducted cell-based experiments. All authors read and approved the final manuscript.

## Funding

This work was supported by the National Natural Science Foundation of China (grant nos. 32270442, 31872219, 31370401, 32030011, 31630071, and 31772448), the National Key Research and Development Program of China (grant no. 2022YFF1301602) and the Postgraduate Research & Practice Innovation Program of Jiangsu Province (grant nos. KYCX23\_1747, KYCX23\_1740 and KYCX23\_1741). The funding bodies for this study had no role in the design of the study, collection of data, data analysis and interpretation, or in writing the manuscript.



### Data availability

Orthologous sequences of 42 pulmonary fibrosis related genes from 45 species and tree of species used in subsequent evolutionary analysis are available in the figshare Dataset (<https://doi.org/10.6084/m9.figshare.24953628.v1>). The data generated and analyzed during this study are included in this article and its additional files, including 11 tables and 10 figures.

### Declarations

#### Competing interests

The authors declare no competing interests.

#### Ethics approval and consent to participate

All animal samples were collected legally and in accordance with the policy of the Animal Research and Ethics Committee of Nanjing Normal University. All animal experiments were approved by the Animal Research and Ethics Committee of Nanjing Normal University (NO: IACUC-20230402). There was no use of human participants, data, or tissues. We confirmed that all methods are reported in accordance with ARRIVE guidelines (<https://arriveguidelines.org>) for the reporting of animal experiments.

#### Consent for publication

Not applicable.

Received: 21 November 2023 / Accepted: 27 March 2024

Published online: 04 April 2024

### References

- Vann RD, Butler FK, Mitchell SJ, Moon RE. Decompression illness. *Lancet*. 2011;377(9760):153–64.
- Mahon RT, Regis DP. Decompression and decompression sickness. *Compr Physiol*. 2014;4(3):1157–75.
- Muth CM, Shank ES. Gas embolism. *N Engl J Med*. 2000;342(7):476–82.
- Sánchez-Villalobos JM, Fortuna-Alcaraz ML, Serrano-Velasco L, Pujante-Escudero A, Garnés-Sánchez CM, Pérez-Garcilazo JE, Olea-González A, Pérez-Vicente JA. Breath-hold diving-related decompression sickness with brain involvement: from neuroimaging to pathophysiology. *Tomography*. 2022;8(3):1172–83.
- Lemaître F, Fahlman A, Gardette B, Kohshi K. Decompression sickness in breath-hold divers: a review. *J Sports Sci*. 2009;27(14):1519–34.
- Blogg SL, Tillmans F, Lindholm P. The risk of decompression illness in breath-hold divers: a systematic review. *Diving Hyperb Med*. 2023;53(1):31–41.
- Anderson W, Murray P, Hertweck K. Dive Medicine: current perspectives and future directions. *Curr Sports Med Rep*. 2019;18(4):129–35.
- DO JH. The risks of scuba diving: a focus on decompression illness. *Hawaii J Med Public Health*. 2014;73(11 Suppl 2):13–6.
- García-Párraga D, Crespo-Picazo JL, Bernaldo de Quirós Y, Cervera V, Martí-Bonmati L, Díaz-Delgado J, Arbelo M, Moore MJ, Jepson PD, Fernández A. Decompression sickness (the bends) in sea turtles. *Dis Aquat Org*. 2014;111(3):191–205.
- Portugues C, Crespo-Picazo JL, García-Párraga D, Altimiras J, Lorenzo T, Borque-Espinosa A, Fahlman A. Impact of gas emboli and hyperbaric treatment on respiratory function of loggerhead sea turtles (*Caretta caretta*). *Conserv Physiol*. 2018;6(1):1–8.
- Zimmer WMX, Tyack PL. REPETITIVE SHALLOW DIVES POSE, DECOMPRESSION RISK IN DEEP-DIVING BEAKED WHALES. *Mar Mammal Sci*. 2007;23(4):888–925.
- Tal D, Shachar-Bener H, Hershkovitz D, Arieli Y, Shupak A. Evidence for the initiation of decompression sickness by exposure to intense underwater sound. *J Neurophysiol*. 2015;114(3):1521–9.
- Fahlman A, Moore MJ, Wells RS. How do Marine mammals manage and usually avoid gas emboli formation and gas Embolic Pathology? Critical clues from studies of Wild dolphins. *Front Mar Sci*. 2021;8.
- Fahlman A. Cardiorespiratory adaptations in small cetaceans and marine mammals. *Exp Physiol*. 2023;00:1–11.
- Fahlman A, Moore MJ, García-Párraga D. Respiratory function and mechanics in pinnipeds and cetaceans. *J Exp Biol*. 2017;220(10):1761–73.
- Fahlman A, Tyack PL, Miller PJOM, Kvadsheim PH. Human disturbances might cause dangerous gas bubbles to form in deep-diving whales. *Front Young Minds*. 2017;5.
- García Párraga D, Moore M, Fahlman A. Pulmonary ventilation–perfusion mismatch: a novel hypothesis for how diving vertebrates may avoid the bends. *Proc Royal Soc B*. 2018;285(1877):20180482.
- Kooyman GL, Sinnott EE. Pulmonary shunts in Harbor Seals and Sea Lions during simulated Dives to depth. *Physiol Zool*. 1982;55(1):105–11.
- McDonald BI, Ponganis PJ. Lung collapse in the diving sea lion: hold the nitrogen and save the oxygen. *Biol Lett*. 2012;8(6):1047–9.
- Ridgway SH, Howard R. Dolphin Lung Collapse and intramuscular circulation during free diving: evidence from Nitrogen Washout. *Science*. 1979;206(4423):1182–3.
- Fahlman A, Loring SH, Johnson SP, Haulena M, Trites AW, Fravel VA, Van Bonn WG. Inflation and deflation pressure–volume loops in anesthetized pinnipeds confirms compliant chest and lungs. *FRONT PHYSIOL*. 2014;5.
- Piscitelli MA, Raverty SA, Lillie MA, Shadwick RE. A review of cetacean lung morphology and mechanics. *J Morphol*. 2013;274(12):1425–40.
- Falke KJ, Hill RD, Qvist J, Schneider RC, Guppy M, Liggins GC, Hochachka PW, Elliott RE, Zapol WM. Seal lungs collapse during free diving: evidence from arterial Nitrogen tensions. *Science*. 1985;229(4713):556–8.
- Huelsmann M, Hecker N, Springer MS, Gatesy J, Sharma V, Hiller M. Genes lost during the transition from land to water in cetaceans highlight genomic changes associated with aquatic adaptations. *Sci Adv*. 2019;5(9):eaaw6671.
- Otero-Sabio C, Centelleghè C, Corain L, Graic J-M, Cozzi B, Rivero M, Consoli F, Peruffo A. Microscopic anatomical, immunohistochemical, and morphometric characterization of the terminal airways of the lung in cetaceans. *J Morphol*. 2021;282(2):291–308.
- Boyd RB. A gross and microscopic study of the respiratory anatomy of the antarctic weddell seal, *Leptonychotes weddelli*. *J Morphol*. 1975;147(3):309–35.
- Henk WG, Haldiman JT. Microanatomy of the lung of the bowhead whale *balaena mysticetus*. *Anat Rec*. 1990;226(2):187–97.
- Ishii H, Kinoshita Y, Kushima H, Nagata N, Watanabe K. The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis. *Chron Respir Dis*. 2019;16:1479973119867945.
- Enomoto N, Suda T, Kono M, Kaida Y, Hashimoto D, Fujisawa T, Inui N, Nakamura Y, Imokawa S, Funai K, et al. Amount of elastic fibers predicts prognosis of idiopathic pulmonary fibrosis. *Resp Med*. 2013;107(10):1608–16.
- Mohanty K, Karbalaiesadegh Y, Blackwell J, Ali M, Masuodi B, Egan T, Muller M. In vivo Assessment of Pulmonary Fibrosis and Pulmonary Edema in rodents using Ultrasound multiple scattering. *IEEE Trans Ultrason Ferroelectr Freq Control*. 2020;67(11):2274–80.
- Yuan J, Chiofolo CM, Czerwin BJ, Karamolegkos N, Chbat NW. Alveolar tissue Fiber and surfactant effects on Lung mechanics—Model Development and Validation on ARDS and IPF patients. *IEEE Open J Eng Med*. 2021;2:44–54.
- Foot NJ, Orgeig S, Daniels CB. The evolution of a physiological system: the pulmonary surfactant system in diving mammals. *Resp Physiol Neurobiol*. 2006;154(1):118–38.
- Spragg RG, Ponganis PJ, Marsh JJ, Rau GA, Bernhard W. Surfactant from diving aquatic mammals. *J Appl Physiol*. 2004;96(5):1626–32.
- Hooker SK, Fahlman A, Moore MJ, Aguilar de Soto N, Bernaldo de Quirós Y, Brubakk AO, Costa DP, Costidis AM, Dennison S, Falke KJ, et al. Deadly diving? Physiological and behavioural management of decompression stress in diving mammals. *Proc Biol Sci*. 2012;279(1731):1041–50.
- Boehme SA, Franz-Bacon K, DiTirro DN, Ly TW, Bacon KB. MAP3K19 is a Novel Regulator of TGF- $\beta$  signaling that impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis. *PLoS ONE*. 2016;11(5):e0154874.
- Boehme SA, Franz-Bacon K, Ludka J, DiTirro DN, Ly TW, Bacon KB. MAP3K19 is overexpressed in COPD and is a central mediator of cigarette smoke-Induced Pulmonary inflammation and lower Airway Destruction. *PLoS ONE*. 2016;11(12):e0167169.
- Hishikawa D, Shindou H, Harayama T, Ogasawara R, Suwabe A, Shimizu T. Identification of Sect. 14-like 3 as a novel lipid-packing sensor in the lung. *FASEB J*. 2013;27(12):5131–40.
- Shan L, Noritake S, Fujiwara M, Asano S, Yoshida-Noro C, Noro N, Yamashita K, Kawakami T. Sec14I3 is specifically expressed in mouse Airway Ciliated cells. *Inflammation*. 2012;35(2):702–12.
- Gutierrez DB, Fahlman A, Gardner M, Kleinhenz D, Piscitelli M, Raverty S, Haulena M, Zimba PV. Phosphatidylcholine composition of pulmonary surfactant from terrestrial and marine diving mammals. *Resp Physiol Neurobiol*. 2015;211:29–36.

40. Kaur A, Mathai SK, Schwartz DA. Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and treatment. *Front Med (Lausanne)*. 2017;4:154–154.
41. Kropski JA, Blackwell TS, Loyd JE. The genetic basis of idiopathic pulmonary fibrosis. *Eur Respir J*. 2015;45(6):1717–27.
42. Yu G, Ibarra GH, Kaminski N. Fibrosis. Lessons from OMICS analyses of the human lung. *Matrix Biol*. 2018;68–69:422–34.
43. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. *Proc Natl Acad Sci U S A*. 2002;99(9):6292–7.
44. Ranwez V, Douzery EJP, Cambon C, Chantret N, Delsuc F. MACSE v2: Toolkit for the alignment of coding sequences accounting for frameshifts and stop codons. *Mol Biol Evol*. 2018;35(10):2582–4.
45. Löytynoja A. Phylogeny-aware alignment with PRANK. *Methods Mol Biol*. 2014;1079:155–70.
46. Talavera G, Castresana J. Improvement of Phylogenies after removing Divergent and ambiguously aligned blocks from protein sequence alignments. *Syst Biol*. 2007;56(4):564–77.
47. Kimura M. The neutral theory of molecular evolution: a review of recent evidence. *Jpn J Genet*. 1991;66(4):367–86.
48. Yang Z, Bielawski JP. Statistical methods for detecting molecular adaptation. *Trends Ecol Evol*. 2000;15(12):496–503.
49. Yang Z. PAML 4: phylogenetic analysis by Maximum Likelihood. *Mol Biol Evol*. 2007;24(8):1586–91.
50. Hurst LD. The Ka/Ks ratio: diagnosing the form of sequence evolution. *Trends Genet*. 2002;18(9):486–7.
51. Yang Z. Maximum likelihood phylogenetic estimation from DNA sequences with variable rates over sites: approximate methods. *J Mol Evol*. 1994;39(3):306–14.
52. Benjamini Y, Hochberg Y. Controlling the false Discovery rate: a practical and powerful Approach to multiple testing. *J R Stat Soc Ser B Stat Methodol*. 1995;57(1):289–300.
53. Swanson WJ, Vacquier VD. The rapid evolution of reproductive proteins. *Nat Rev Genet*. 2002;3(2):137–44.
54. Zhang J, Nielsen R, Yang Z. Evaluation of an Improved Branch-Site Likelihood Method for detecting positive selection at the Molecular Level. *Mol Biol Evol*. 2005;22(12):2472–9.
55. Kosiol C, Vinař T, da Fonseca RR, Hubisz MJ, Bustamante CD, Nielsen R, Siepel A. Patterns of positive selection in six mammalian genomes. *PLoS Genet*. 2008;4(8):e1000144.
56. Huang X, Sun D, Wu T, Liu X, Xu S, Yang G. Genomic insights into body size evolution in Carnivora support Peto's paradox. *BMC Genom*. 2021;22(1):429.
57. Posada D, Buckley TR. Model selection and Model Averaging in Phylogenetics: advantages of Akaike Information Criterion and bayesian approaches over likelihood ratio tests. *Syst Biol*. 2004;53(5):793–808.
58. Sun Y-B. FasParser2: a graphical platform for batch manipulation of tremendous amount of sequence data. *Bioinformatics*. 2018;34(14):2493–5.
59. Consortium TU. UniProt: the Universal protein knowledgebase in 2023. *Nucleic Acids Res*. 2023;51(D1):D523–31.
60. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer TAP, Rempfer C, Bordoli L, et al. SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic Acids Res*. 2018;46(W1):W296–303.
61. Finn RD, Bateman A, Clements J, Coggill P, Eberhardt RY, Eddy SR, Heeger A, Hetherington K, Holm L, Mistry J, et al. Pfam: the protein families database. *Nucleic Acids Res*. 2013;42(D1):D222–30.
62. Reynolds CR, Islam SA, Sternberg MJE, EzMol. A web server Wizard for the Rapid Visualization and Image Production of Protein and nucleic acid structures. *J Mol Biol*. 2018;430(15):2244–8.
63. Boddy AM, Harrison PW, Montgomery SH, Caravas JA, Raghanti MA, Phillips KA, Mundy NI, Wildman DE. Evidence of a conserved molecular response to selection for increased brain size in Primates. *Genome Biol Evol*. 2017;9(3):700–13.
64. Montgomery SH, Capellini I, Venditti C, Barton RA, Mundy NI. Adaptive evolution of four Microcephaly genes and the evolution of brain size in Anthropoid Primates. *Mol Biol Evol*. 2010;28(1):625–38.
65. Pennell MW. Modern Phylogenetic Comparative Methods and Their Application in Evolutionary Biology: Concepts and Practice. — Edited by László Zsolt Garamszegi. *Syst Biol*. 2014;64(1):161–163.
66. Pagel M. Inferring the historical patterns of biological evolution. *Nature*. 1999;401(6756):877–84.
67. Orme D, Freckleton R, Thomas G, Petzoldt T, Fritz S, Isaac N. Pearse WJRpv. The caper package: comparative analysis of phylogenetics and evolution in R. R Package Version. 2013;5(2):1–36.
68. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene Ontology: tool for the unification of biology. *Nat Genet*. 2000;25(1):25–9.
69. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat Commun*. 2019;10(1):1523.
70. Aguilera G, Refrégier G, Yockteng R, Fournier E, Giraud T. Rapidly evolving genes in pathogens: methods for detecting positive selection and examples among fungi, bacteria, viruses and protists. *Infect Genet Evol*. 2009;9(4):656–70.
71. Sun L, Rong X, Liu X, Yu Z, Zhang Q, Ren W, Yang G, Xu S. Evolutionary genetics of flipper forelimb and hindlimb loss from limb development-related genes in cetaceans. *BMC Genom*. 2022;23(1):797.
72. Pardo A, Cabrera S, Maldonado M, Selman M. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. *Respir Res*. 2016;17(1):23.
73. Law RHP, Zhang Q, McGowan S, Buckle AM, Silverman GA, Wong W, Rosado CJ, Langendorf CG, Pike RN, Bird PI, et al. An overview of the serpin superfamily. *Genome Biol*. 2006;7(5):216.
74. Twigg MS, Brockbank S, Lowry P, FitzGerald SP, Taggart C, Weldon S. The role of serine proteases and Antiproteases in the cystic fibrosis lung. *Mediators Inflamm*. 2015;2015:293053.
75. Muntané G, Farré X, Rodríguez JA, Pegueroles C, Hughes DA, de Magalhães JP, Gabaldón T, Navarro A. Biological processes modulating longevity across Primates: a phylogenetic genome-phenome analysis. *Mol Biol Evol*. 2018;35(8):1990–2004.
76. Katzen J, Wagner BD, Venosa A, Kopp M, Tomer Y, Russo SJ, Headen AC, Basil MC, Stark JM, Mulugeta S, et al. An SFTPC BRICHOS mutant links epithelial ER stress and spontaneous lung fibrosis. *JCI Insight*. 2019;4(6):e126125.
77. Tian R, Wang Z, Niu X, Zhou K, Xu S, Yang G. Evolutionary Genetics of Hypoxia Tolerance in cetaceans during diving. *Genome Biol Evol*. 2016;8(3):827–39.
78. Yim H-S, Cho YS, Guang X, Kang SG, Jeong J-Y, Cha S-S, Oh H-M, Lee J-H, Yang EC, Kwon KK, et al. Minke whale genome and aquatic adaptation in cetaceans. *Nat Genet*. 2014;46(1):88–92.
79. McGowan MR, Gatesy J, Wildman DE. Molecular evolution tracks macroevolutionary transitions in Cetacea. *Trends Ecol Evol*. 2014;29(6):336–46.
80. Hermes-Lima M, Moreira DC, Rivera-Ingraham GA, Giraud-Billoud M, Genaro-Mattos TC, Campos ÉG. Preparation for oxidative stress under hypoxia and metabolic depression: revisiting the proposal two decades later. *Free Radic Biol Med*. 2015;89:1122–43.
81. Bahudhanapati H, Tan J, Dutta JA, Strock SB, Sembrat J, Álvarez D, Rojas M, Jäger B, Prasse A, Zhang Y, et al. MicroRNA-144-3p targets relaxin/insulin-like family peptide receptor 1 (RXFP1) expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis. *J Biol Chem*. 2019;294(13):5008–22.
82. Tan J, Tedrow JR, Dutta JA, Juan-Guardela B, Nouraei M, Chu Y, Bittar HT, Ramani K, Biswas PS, Veraldi KL, et al. Expression of RXFP1 is decreased in idiopathic pulmonary fibrosis. Implications for Relaxin-based therapies. *Am J Respir Crit Care Med*. 2016;194(11):1392–402.
83. Erlandson SC, Rawson S, Osei-Owusu J, Brock KP, Liu X, Paulo JA, Mintseris J, Gygi SP, Marks DS, Cong X, et al. The relaxin receptor RXFP1 signals through a mechanism of autoinhibition. *Nat Chem Biol*. 2023;19(8):1013–21.
84. Fang L, Che Y, Zhang C, Huang J, Lei Y, Lu Z, Sun N, He J. PLAU directs conversion of fibroblasts to inflammatory cancer-associated fibroblasts, promoting esophageal squamous cell carcinoma progression via uPAR/Akt/NF-κB/IL8 pathway. *Cell Death Discov*. 2021;7(1):32.
85. Zhou X, Guang X, Sun D, Xu S, Li M, Seim I, Jie W, Yang L, Zhu Q, Xu J, et al. Population genomics of finless porpoises reveal an incipient cetacean species adapted to freshwater. *Nat Commun*. 2018;9(1):1276.
86. Shmakova AA, Popov VS, Romanov IP, Khabibullin NR, Sabitova NR, Karpukhina AA, Kozhevnikova YA, Kurilina EV, Tsokolaeva ZI, Klimovich PS, et al. Urokinase system in Pathogenesis of Pulmonary Fibrosis: a hidden threat of COVID-19. *Int J Mol Sci*. 2023;24(2):1382.
87. Gochuico BR, Huizing M, Golas GA, Scher CD, Tsokos M, Denver SD, Frei-Jones MJ, Gahl WA. Interstitial lung Disease and Pulmonary Fibrosis in Hermansky-Pudlak syndrome type 2, an adaptor Protein-3 Complex Disease. *Mol Med*. 2012;18(1):56–64.
88. Simpson F, Peden AA, Christopoulou L, Robinson MS. Characterization of the adaptor-related protein complex, AP-3. *J Cell Biol*. 1997;137(4):835–45.

89. Mecham RP. Elastin in lung development and disease pathogenesis. *Matrix Biol.* 2018;73:6–20.
90. Bhana RH, Magan AB. Lung mechanics: a review of solid mechanical elasticity in Lung Parenchyma. *J Elast.* 2023;153(1):53–117.
91. Scholander PF. Experimental investigations on the respiratory function in diving mammals and birds. Oslo: I kommisjon hos Jacob Dybwad; 1940.
92. Embloom-Callahan MC, Chhina MK, Shlobin OA, Ahmad S, Reese ES, Iyer EPR, Cox DN, Brenner R, Burton NA, Grant GM, et al. Genomic phenotype of non-cultured pulmonary fibroblasts in idiopathic pulmonary fibrosis. *Genomics.* 2010;96(3):134–45.
93. Sneha Sitaraman K-DA, Wambach JA, Limberis. Gene therapeutics for surfactant dysfunction disorders: targeting the alveolar type 2 epithelial cell. *Hum Gene Ther.* 2022;33(19–20):1011–22.
94. Cooney AL, Wambach JA, Sinn PL, McCray PB. Gene Therapy Potential for Genetic Disorders of Surfactant Dysfunction. *Front Genet.* 2022;3.
95. Xue J, Gochuico BR, Alawad AS, Feghali-Bostwick CA, Noth I, Nathan SD, Rosen GD, Rosas IO, Dacic S, Ocak I, et al. The HLA Class II Allele DRB1\*1501 is over-represented in patients with idiopathic pulmonary fibrosis. *PLoS ONE.* 2011;6(2):e14715.
96. Hata A, Nakajima T, Matsusaka K, Fukuyo M, Nakayama M, Morimoto J, Ito Y, Yamamoto T, Sakairi Y, Rahmutulla B, et al. Genetic alterations in squamous cell lung cancer associated with idiopathic pulmonary fibrosis. *Int J Cancer.* 2021;148(12):3008–18.
97. Hu Y, Wang X, Xu Y, Yang H, Tong Z, Tian R, Xu S, Yu L, Guo Y, Shi P, et al. Molecular mechanisms of adaptive evolution in wild animals and plants. *Sci China Life Sci.* 2023;66(3):453–95.
98. Bueno M, Lai Y-C, Romero Y, Brands J, St. Croix CM, Kamga C, Corey C, Herazo-Maya JD, Sembrat J, Lee JS, et al. PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. *J Clin Invest.* 2015;125(2):521–38.
99. Orgeig S, Hiemstra PS, Veldhuizen EJA, Casals C, Clark HW, Haczk A, Knudsen L, Possmayer F. Recent advances in alveolar biology: evolution and function of alveolar proteins. *Respir Physiol Neurobiol.* 2010;173:S43–54.
100. Willander H, Askarieh G, Landreh M, Westermarck P, Nordling K, Keränen H, Hermansson E, Hamvas A, Nogee LM, Bergman T, et al. High-resolution structure of a BRICHOS domain and its implications for anti-amyloid chaperone activity on lung surfactant protein C. *Proc Natl Acad Sci U S A.* 2012;109(7):2325–9.
101. Mulugeta S, Nguyen V, Russo SJ, Muniswamy M, Beers MF, A Surfactant Protein C. Precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, Proteasome Dysfunction, and Caspase 3 activation. *Am J Respir Cell Mol Biol.* 2005;32(6):521–30.
102. Blackwell TS. Lung injury and fibrosis induced by a mutant form of surfactant protein C. *J Clin Invest.* 2018;128(9):3745–6.
103. Abdel Megeid AK, Refeat MM, Ashaat EA, El-Kamah G, El-Saiedi SA, Elfalaki MM, El Ruby MO, Amr KS. Correlating SFTPC gene variants to interstitial lung disease in Egyptian children. *J Genet Eng Biotechnol.* 2022;20(1):117.
104. Furukawa T, Akaike K, Iyama S, Masunaga A, Tomita Y, Saeki S, Ichiyasu H, Sakagami T. Interstitial Lung Disease in Adulthood Associated with Surfactant Protein C Gene Mutation in a patient with a history of Lipoid Pneumonia in Infancy. *Intern Med.* 2023;62(17):2521–5.
105. Wang W-J, Mulugeta S, Russo SJ, Beers MF. Deletion of exon 4 from human surfactant protein C results in aggresome formation and generation of a dominant negative. *J Cell Sci.* 2003;116(4):683–92.
106. Chibbar R, Shih F, Baga M, Torlakovic E, Ramlall K, Skomro R, Cockcroft DW, Lemire EG. Nonspecific interstitial pneumonia and usual interstitial pneumonia with mutation in surfactant protein C in familial pulmonary fibrosis. *Mod Pathol.* 2004;17(8):973–80.
107. Maguire JA, Mulugeta S, Beers MF. Multiple ways to die: Delineation of the unfolded protein response and apoptosis induced by Surfactant Protein C BRICHOS mutants. *Int J Biochem Cell Biol.* 2012;44(1):101–12.
108. Kabore AF, Wang W-J, Russo SJ, Beers MF. Biosynthesis of surfactant protein C: characterization of aggresome formation by EGFP chimeras containing pro-peptide mutants lacking conserved cysteine residues. *J Cell Sci.* 2001;114(Pt 2):293–302.
109. Wert SE, Whitsett JA, Nogee LM. Genetic disorders of surfactant dysfunction. *Pediatr Dev Pathol.* 2009;12(4):253–74.
110. Qiu Y, Pan X, Hu Y. Polydatin ameliorates pulmonary fibrosis by suppressing inflammation and the epithelial mesenchymal transition via inhibiting the TGF- $\beta$ /Smad signaling pathway. *RSC Adv.* 2019;9(14):8104–12.
111. Nosoh Y, Sekiguchi T. Protein engineering for thermostability. *Trends Biotechnol.* 1990;8(1):16–20.
112. Henson PM, Vandivier RW, Douglas IS. Cell death, remodeling, and Repair in Chronic Obstructive Pulmonary Disease? *Proc Am Thorac Soc.* 2006;3(8):713–7.
113. Park J-W, Ryter SW, Choi AMK. Functional significance of apoptosis in Chronic Obstructive Pulmonary Disease. *COPD.* 2007;4(4):347–53.
114. Korfei M, Ruppert C, Mahavadi P, Henneke I, Markart P, Koch M, Lang G, Fink L, Bohle R-M, Seeger W, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2008;178(8):838–46.
115. Borok Z, Horie M, Flodby P, Wang H, Liu Y, Ganesh S, Firth AL, Minoo P, Li C, Beers MF, et al. Grp78 loss in epithelial progenitors reveals an age-linked role for endoplasmic reticulum stress in Pulmonary Fibrosis. *Am J Respir Crit Care Med.* 2020;201(2):198–211.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

[onlineservice@springernature.com](mailto:onlineservice@springernature.com)